AbbVie Inc.: U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease · Ereignisanalyse & Evidenz

BoerseAI

AbbVie Inc.: U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease · Ereignisanalyse & Evidenz · BoerseAI

Ereignis wird geladen …